Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.

NCT00551473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease
Reflux, Gastroesophageal

Interventions

DRUG: Lavoltidine

Sponsor

GlaxoSmithKline